Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Both Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month before insurance ... In response, Eli Lilly ...

Both Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month ... Eli Lilly reduced the monthly price of lower-dosage vials of Zepbound by $50 for cash-paying consumers ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss ...